The Food and Drug Administration yesterday issued a warning letter to CanaRx, a company that contracts with employers to provide select prescription drugs to employees, for facilitating the distribution of unapproved and misbranded drugs. “In this scheme, CanaRx facilitates foreign physicians rewriting the employee’s U.S. prescription, and then supplies the employee with unapproved versions of FDA-approved drugs purportedly sourced from Canada, the United Kingdom or Australia that are represented to have undergone review from those countries’ drug regulatory systems,” FDA said. “This is particularly troublesome, as employees are likely inclined to trust that they will receive safe and effective drugs through their employer’s ‘insurance’ plan and may not question their legitimacy.” The letter lists more than 150 websites affiliated with the company. FDA said health care providers and consumers should report any adverse events related to drugs provided by CanaRx to its MedWatch program.

Related News Articles

Headline
The 2025 AHA Annual Membership Meeting began today with Joanne Conroy, M.D., president and CEO of Dartmouth Health and 2024 AHA board chair, discussing the…
Headline
Rep. Nathaniel Moran, R-Texas, and Rep. Brad Schneider, D-Ill., both members of the House Ways and Means Committee, spoke to the AHA Annual Membership Meeting…
Headline
Rep. Mariannette Miller-Meeks, R-Iowa, participated in a fireside chat during the afternoon plenary session today at the 2025 AHA Annual Membership meeting. As…
Headline
Stacey Hughes, AHA's executive vice president for government relations and public policy, discussed key issues being considered on Capitol Hill that would…
Headline
John Ashbrook, founding partner, Cavalry LLC, and co-host of the Ruthless Podcast, yesterday moderated a panel discussion between Leigh Ann Caldwell, chief…
Headline
President Trump today released his discretionary spending budget blueprint for fiscal year 2026. The “skinny budget” request, which includes top line…